HELP
Cybin D/B/A Helus Pharma (NASDAQ)
Healthcare — Biotechnology
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Price History
Fundamentals
| Market Cap | $389.32M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.18 |
| EPS (TTM) | $-4.25 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -73.68% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $41.98 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 82.5 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.12 |
| 52-Week Low | $3.76 |
| 50-Day Avg | $4.94 |
| 200-Day Avg | $5.98 |
| Avg Volume | $1.24M |
| Volume | $2.04M |
Performance Analysis
BULLISHHELP shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:13 UTC
Back to Screener Export Report